Description |
PXD101 is a novel investigational small molecule drug that inhibits the enzyme histone deacetylase (HDAC). PXD101 has been shown in preclinical studies to have the potential to treat a wide range of solid and hematologic malignancies either as a monotherapy or in combination with other active agents, and both an oral and intravenous formulation of the drug are being evaluated in clinical trials.
|
